Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1621978 | 0.82 | PIK3CB (0.60) | SLC22A12EGFRPIK3CBNAMPTMEN1 | |
| SCHEMBL381261 | 0.79 | MEN1 (0.60) | SLC22A12EGFRHSD17B2MEN1ALDH1A1 | |
| SCHEMBL791411 | 0.79 | SLC22A12 (0.60) | SLC22A12EGFRSMN1; SMN2PIK3CBHTR6 | |
| SCHEMBL3119732 | 0.72 | SLC22A12 (0.46) | SLC22A12EGFRSMN1; SMN2PIK3CBMEN1 | |
| SCHEMBL22914715 | 0.70 | MEN1 (0.56) | SMN1; SMN2MEN1ALDH1A1LMNAMAPT | |
| SCHEMBL856308 | 0.70 | PIK3CB (0.54) | SLC22A12PIK3CBNAMPTPTGS1PTGS2 | |
| SCHEMBL18702879 | 0.68 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1LMNAGAAMAPT | |
| SCHEMBL783480 | 0.68 | CYP11B2 (0.41) | SMN1; SMN2MEN1ALDH1A1LMNATP53 | |
| SCHEMBL3472642 | 0.68 | CYP11B2 (0.41) | SMN1; SMN2MEN1ALDH1A1LMNATP53 | |
| SCHEMBL3511669 | 0.68 | CYP11B2 (0.41) | SMN1; SMN2MEN1ALDH1A1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183232-B1 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-7928140-B2 | Benzothiazole PI3 kinase modulators for cancer treatment | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2183232-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | Amgen, Inc (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009017822-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054405-A1 | PI3 kinase modulators and methods of use | PIK3CA, PIK3C2A, PIK3C2B | SLC22A12 4255/4885EGFR 475/4885SMN1; SMN2 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.